ASP2138
Solid Tumors
Key Facts
About Astellas
Astellas Pharma is a major global pharmaceutical company with a mission to deliver innovative, patient-centric healthcare solutions. Formed in 2005 from the merger of Yamanouchi and Fujisawa, it has established a robust pipeline and commercial portfolio across oncology, urology, immunology, and other therapeutic areas. The company's strategy is built on a multi-modal R&D engine focused on cutting-edge biology, complemented by aggressive external innovation and a strategic push into digital health through its Rx+ and HealthX initiatives to drive sustainable growth.
View full company profileAbout Astellas Pharma
Astellas Pharma is a Japan-based global pharmaceutical leader with a mission to deliver transformative therapies in areas of high unmet medical need. Formed by the 2005 merger of Yamanouchi and Fujisawa, the company has grown into a $45.8 billion market cap entity with a vertically integrated model spanning R&D, manufacturing, and global commercialization. Its strategy is anchored in a patient-centric approach, a robust pipeline, and strategic external innovation to drive growth in core therapeutic areas and next-generation modalities.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |